Characteristics associated with reported sputum culture conversion in the era of re-emergent Mycobacterium tuberculosis in the State of North Carolina, 1993-1998

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 11, 2003, Pages 1070-1076

  Salihu, H M ^a   Aliyu, Muktar H ^a   Ratard, R ^b   Pierre Louis, B J ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

HIV; Population based study; Sputum conversion; Tuberculosis

Indexed keywords

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; SPUTUM CULTURE; SUPERINFECTION; SURVIVAL; SYMBIOSIS; UNITED STATES;

COMORBIDITY; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA; PROPORTIONAL HAZARDS MODELS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0242583990     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cantwell M F, Snider D E, Cauthen G M, Onorato I M. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272: 535-539.
2. The continuing challenge of tuberculosis. OTA publication H-574. Washington, DC: US congress, Office of Technology Assessment, 1993.
3. American Thoracic Society. Control of Tuberculosis in the United States. Am Rev Respir Dis 1992; 146: 1623-1633.
4. Leads from the Morbidity and Mortality Weekly Report, Atlanta, Ga: Expanded tuberculosis surveillance and tuberculosis morbidity-United States, 1993. JAMA 1994; 272: 265-266.
5. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1994. Morb Mortal Wkly Rep 1995; 44: 387-389.
6. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1995. Morb Mortal Wkly Rep 1996; 45: 365-370.
7. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1996. Morb Mortal Wkly Rep 1997; 46: 695-700.
8. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1997. Morb Mortal Wkly Rep 1998; 47: 253-257.
9. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 229-233.
10. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
11. Liu Z, Shilkret K L, Ellis H M. Predictors of sputum conversion among patients with tuberculosis in the era of tuberculosis resurgence. Arch Intern Med 1999; 159: 1110-1116.
12. Centers for Disease Control. Case definitions for public health surveillance. Morb Mortal Wkly Rep 1990; 39(RR-13): 39-40.
13. Bloch A B, Onorato I M, Ihle W W, Hadler J L, Hayden C H, Snider D E Jr. Expanded tuberculosis surveillance in the United States: the need for epidemic intelligence. Public Health Rep 1996; 11: 26-31.
14. Centers for Disease Control and Prevention. SURVS-TB: Software for Expanded Tuberculosis Surveillance. Version 2.0. Atlanta, GA: Centers for Disease Control and Prevention, 1994.
15. Hong Kong Chest Service, British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
16. Castelo A, Jardim J R B, Goihman S, et al. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989; 2: 1173-1176.
17. Perriëns J H, Colebunders R L, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus seropositive compared with HIV sero-negative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755.
18. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with HIV infection. N Engl J Med 1989; 320: 545-550.
19. Centers for Disease Control and Prevention. Progress toward the elimination of tuberculosis-United States, 1998. Morb Mortal Wkly Rep 1999; 27: 732-736.
20. Sortir M J, Parrott P, Metchock B, et al. Tuberculosis in the inner city: impact of a continuing epidemic in the 1990s. Clin Infect Dis 1999; 29: 1138-1144.
21. Markowitz N, Hansen N I, Hopewell P C, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997; 126: 123-132.
22. Brindle I J, Nunn P P, Githui W, Allen B W, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993; 147: 958-961.
23. Telzak E E, Fazal B A, Pollard C L, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666-670.
24. Perriëns J H, St. Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
25. Katz D J, Hall W N, Keon N B, Crane L R. HIV testing in patients with tuberculosis: physician response to national recommendations. Am Rev Respir Dis 1993; 147: 1283-1286.
26. Asch S M, London A S, Barnes P F, Gelberg L. Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Am J Respir Crit Care Med 1997; 155: 378-381.
27. Salihu H M, Naik E, O'Brien W F, Dagne G, Ratard R, Mason T. Tuberculosis in North Carolina: trends across two decades, 1980-1999. Emerg Infect Dis 2001; 7 (Suppl): 570-574.
28. Combs D L, O'Brien R J, Geiter L J. USPHS TB short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann Intern Med 1990; 112: 397-406.